PMID- 32793717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 14
DP  - 2020 Jul
TI  - Efficacy and safety of transcatheter aortic valve implantation in patients with 
      severe bicuspid aortic stenosis.
PG  - 873
LID - 10.21037/atm-20-4436 [doi]
LID - 873
AB  - BACKGROUND: Bicuspid aortic valve (BAV) is common congenital malformation, 
      bicuspid aortic stenosis accounts for a substantial proportion of patients with 
      aortic valve stenosis (AS). Bicuspid AS are more likely to have aortic dilatation 
      with slightly less elliptical annuli, which might lead to paravalvular aortic 
      valve regurgitation (AR) and permanent pacemaker implantation (PPM) after TAVI 
      with higher mortality. Our study aims to understand the therapeutic efficacy and 
      safety of transcatheter aortic valve implantation (TAVI) with a supra-annular 
      structure-based sizing strategy in Chinese AS patients with BAV versus tricuspid 
      aortic valve (TAV). METHODS: Seventy-four consecutive tricuspid AS patients and 
      44 bicuspid AS patients were included and enrolled in the study for analysis. 
      Both groups underwent TAVI performed using balloon sizing less than mild 
      paravalvular AR to assess the proper prosthesis size. The myocardial function 
      within 1 year postoperative were sequentially evaluated using the New York Heart 
      Association (NYHA) class, and echocardiography measurements. The incidence rates 
      of complications at 30 days and 1 year were analyzed. During the 1-year 
      follow-up, the time of death from any cause or complications in both groups was 
      recorded. RESULTS: The study found that the percentage of patients with class 
      III-IV of NYHA dropped after TAVI in both groups, and no significant difference 
      between both groups at 1 year. Compared with the tricuspid AS group patients, 
      Bicuspid group patients had more improvement in mean aortic valve gradient from 
      baseline to 1year (-47.47+/-13.38 vs. -50.22+/-19.25 mmHg, P<0.05). There were no 
      significant differences in 30-day and one-year compliance outcomes except a lower 
      incidence of AR at post-procedure and 30 days in the tricuspid AS group as the 
      Bicuspid AS group. There were no statistically significant differences in the 
      time of death from any cause or significant complications between groups. 
      CONCLUSIONS: TAVI has acceptable therapeutic efficacy and safety and is feasible 
      for AS patients with BAV in China.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Fu, Bo
AU  - Fu B
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Chen, Qingliang
AU  - Chen Q
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Zhao, Feng
AU  - Zhao F
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Guo, Zhigang
AU  - Guo Z
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Jiang, Nan
AU  - Jiang N
AD  - Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.
FAU - Wang, Xu
AU  - Wang X
AD  - Department of Cardiovascular Surgery, Fuwai Hospital, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Cardiovascular Surgery, Fuwai Hospital, Beijing, China.
FAU - Han, Jiange
AU  - Han J
AD  - Department of Anesthesiology, Tianjin Chest Hospital, Tianjin, China.
FAU - Yang, Li
AU  - Yang L
AD  - Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.
FAU - Zhu, Yanbo
AU  - Zhu Y
AD  - Department of Echocardiography, Tianjin Chest Hospital, Tianjin, China.
FAU - Ma, Yanhe
AU  - Ma Y
AD  - Department of Radiology, Tianjin Chest Hospital, Tianjin, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7396751
OTO - NOTNLM
OT  - Transcatheter aortic valve implantation (TAVI)
OT  - aortic valve stenosis (AS)
OT  - bicuspid aortic valve (BAV)
OT  - tricuspid aortic valve (TAV)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-4436). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
PMCR- 2020/07/01
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
PHST- 2020/07/01 00:00 [pmc-release]
AID - atm-08-14-873 [pii]
AID - 10.21037/atm-20-4436 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Jul;8(14):873. doi: 10.21037/atm-20-4436.